Thyroid eye disease (TED) is the most common extra thyroidal manifestation of Graves'
disease (GD). It may also present in those who are hypothyroid or euthyroid. The …

Context Thyroid eye disease (TED) is a sight-threatening and debilitating autoimmune
condition, with limited therapies available, that often poses diagnostic and therapeutic …

Insulin-like growth factor I receptor (IGF1R) is frequently upregulated in breast cancer. Due
to its intrinsic tyrosine kinase activity, aberrant activation of the IGF1R signaling axis may …

Thyroid eye disease (TED), an autoimmune inflammatory disorder affecting the orbit,
exhibits a range of clinical manifestations. While the disease presentation can vary, cases …

Purpose To assess the duration, incidence, reversibility, and severity of adverse events
(AEs) in patients with thyroid eye disease (TED) treated with teprotumumab. Design …

Introduction Graves' disease (GD) is an autoimmune disorder caused by autoantibodies
against the thyroid stimulating hormone receptor (TSHR) leading to overstimulation of the …

Teprotumumab (TEPEZZA®), a monoclonal antibody that inhibits the insulin-like growth
factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment …

Graves' orbitopathy (GO) is an autoimmune orbital disease mostly associated with Graves'
hyperthyroidism, causing disfiguring signs (exophthalmos, periorbital swelling, strabismus) …

Context Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and
disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the …

Thyroid Eye Disease (TED) is a debilitating autoimmune condition often associated with
thyroid dysfunction, leading to significant ocular and orbital morbidity. This review explores …